zeste基因增强子同源物2(enhancer of zeste homolog 2，EZH2)是一种组蛋白赖氨酸甲基转移酶，可通过调控组蛋白H3在赖氨酸27位点的三甲基化(trimethylation of Lys27 in histone 3，H3K27me3)，诱导靶基因沉默，在腹膜透析(peritoneal dialysis，PD)相关性腹膜纤维化过程中发挥重要作用。研究显示EZH2在腹膜纤维化过程中高表达，通过促进上皮细胞—间充质转化(epithelial-to-mesenchymal transition，EMT)、腹膜炎症和血管新生来促进腹膜纤维化的发生发展，抑制EZH2可抑制甚至部分逆转腹膜纤维化。深入研究EZH2有助于进一步明确腹膜纤维化的发病机制，并为腹膜纤维化的靶向治疗提供参考。
Enhancer of zeste homolog 2 (EZH2) is a histone lysine methyltransferase, which induces the silence of target gene by regulating trimethylation of Lys27 in histone 3 (H3K27me3) and plays an important role in peritoneal dialysis-associated peritoneal fibrosis. Studies have shown that EZH2 is highly expressed in the process of peritoneal fibrosis and induces the development of peritoneal fibrosis by promoting epithelial-to-mesenchymal transition (EMT), peritoneal inflammation and angiogenesis. Inhibition of EZH2 can reduce or even partially reverse peritoneal fibrosis. Further study of EZH2 can be helpful to clarify the pathogenesis of peritoneal fibrosis and to find out target treatment for peritoneal fibrosis.
参考文献
[1] HIMMELFARB J, VANHOLDER R, MEHROTRA R, et al. The current and future landscape of dialysis[J]. Nat Rev Nephrol, 2020,16(10): 573-585.
[2] KREDIET R T. Ultrafiltration Failure Is a Reflection of Peritoneal Alterations in Patients Treated With Peritoneal Dialysis[J]. Frontiers in Physiology, 2018,9.
[3] XUE T, QIU X, LIU H, et al. Epigenetic regulation in fibrosis progress[J]. Pharmacological Research, 2021,173: 105910.
[4] SHI Y, TAO M, WANG Y, et al. Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis[J]. The Journal of Pathology, 2020,250(1): 79-94.
[5] BALZER M S. Molecular pathways in peritoneal fibrosis[J]. Cell Signal, 2020,75: 109778.
[6] MASOLA V, BONOMINI M, BORRELLI S, et al. Fibrosis of Peritoneal Membrane as Target of New Therapies in Peritoneal Dialysis[J]. International Journal of Molecular Sciences, 2022,23(9): 4831.
[7] 马龙飞, 杜路, 邓喜文, 等. 腹膜透析相关性腹膜纤维化机制的研究进展[J]. 中国血液净化, 2022,21(06): 445-448.
[8] DUAN R, DU W, GUO W. EZH2: a novel target for cancer treatment[J]. Journal of Hematology & Oncology, 2020,13(1).
[9] YANG F L, WEI Y X, LIAO B Y, et al. LncRNA HOTAIR regulates the expression of E-cadherin to affect nasopharyngeal carcinoma progression by recruiting histone methylase EZH2 to mediate H3K27 trimethylation[J]. Genomics, 2021,113(4): 2276-2289.
[10] ZIMMERMAN S M, NIXON S J, CHEN P Y, et al. Ezh2(Y641F) mutations co-operate with Stat3 to regulate MHC class I antigen processing and alter the tumor immune response in melanoma[J]. Oncogene, 2022,41(46): 4983-4993.
[11] ZHANG Q, YANG H, FENG Q, et al. Focus on the classical and non-classical functions of EZH2: Guide the development of inhibitors and degraders[J]. Pharmacological Research, 2022,178: 106159.
[12] ZHOU X, XIONG C, TOLBERT E, et al. Targeting histone methyltransferase enhancer of zeste homolog‐2 inhibits renal epithelial‐mesenchymal transition and attenuates renal fibrosis[J]. The FASEB Journal, 2018,32(11): 5976-5989.
[13] JIANG Y, XIANG C, ZHONG F, et al. Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis[J]. Theranostics, 2021,11(1): 361-378.
[14] LI T, YU C, ZHUANG S. Histone Methyltransferase EZH2: A Potential Therapeutic Target for Kidney Diseases[J]. Frontiers in Physiology, 2021,12.
[15] SHI Y, LI J, CHEN H, et al. Inhibition of EZH2 suppresses peritoneal angiogenesis by targeting a VEGFR2/ERK1/2/HIF-1α dependent signaling pathway [J]. The Journal of Pathology, 2022,258(2): 164-178.
[16] MAHALANOBISH S, SAHA S, DUTTA S, et al. Matrix metalloproteinase: An upcoming therapeutic approach for idiopathic pulmonary fibrosis[J]. Pharmacol Res, 2020,152: 104591.
[17] NORGARD R J, PITARRESI J R, MADDIPATI R, et al. Calcium signaling induces a partial EMT[J]. EMBO Rep, 2021,22(9): e51872.
[18] DUAN W, YU X, HUANG X, et al. Opposing Roles for Smad2 and Smad3 in Peritoneal Fibrosis in?Vivo and in?Vitro[J]. The American Journal of Pathology, 2014,184(8): 2275-2284.
[19] WEN L, TAO S, GUO F, et al. Selective EZH2 inhibitor zld1039 alleviates inflammation in cisplatin-induced acute kidney injury partially by enhancing RKIP and suppressing NF-κB p65 pathway[J]. Acta pharmacologica Sinica, 2021,43(8): 2067-2080.
[20] ZHU N, GUAN H, WANG X, et al. EZH2 promotes angiogenesis in peritoneal dialysis by epigenetically activating SP4 expression in the IL-6/sIL-6R signalling pathway[J]. International Journal of Medical Sciences, 2023,20(1): 114-124.
[21] MITI? T, CAPORALI A, FLORIS I, et al. EZH2 Modulates Angiogenesis In Vitro and in a Mouse Model of Limb Ischemia[J]. Molecular therapy, 2015,23(1): 32-42.
[22] WANG Q, XU L, ZHANG X, et al. GSK343, an inhibitor of EZH2, mitigates fibrosis and inflammation mediated by HIF-1alpha in human peritoneal mesothelial cells treated with high glucose[J]. Eur J Pharmacol, 2020,880: 173076.
